Share This Page
Drug Price Trends for FYCOMPA
✉ Email this page to a colleague
Average Pharmacy Cost for FYCOMPA
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FYCOMPA 0.5 MG/ML ORAL SUSP | 69616-0290-38 | 4.46569 | ML | 2025-04-23 |
| FYCOMPA 10 MG TABLET | 69616-0280-30 | 39.16064 | EACH | 2025-04-23 |
| FYCOMPA 12 MG TABLET | 62856-0282-30 | 39.24901 | EACH | 2025-04-23 |
| FYCOMPA 10 MG TABLET | 62856-0280-30 | 39.16064 | EACH | 2025-04-23 |
| FYCOMPA 8 MG TABLET | 69616-0278-30 | 39.17668 | EACH | 2025-04-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for FYCOMPA
Introduction to FYCOMPA
FYCOMPA, also known as perampanel, is a prescription medication used in the treatment of epilepsy. It is a selective non-competitive AMPA receptor antagonist, approved for use in people with epilepsy aged 4 and older for partial-onset seizures, and for those aged 12 and older for primary generalized tonic-clonic seizures[1,.
Market Acquisition and Integration
In January 2023, Catalyst Pharmaceuticals completed the acquisition of the U.S. rights to FYCOMPA from Eisai for $160 million upfront, along with milestone and royalty payments. This acquisition is part of Catalyst's strategy to expand its presence in neuroscience and diversify its revenue streams[4].
Current Market Performance
Since the acquisition, FYCOMPA has performed exceptionally well. For the full year 2023, FYCOMPA's net revenues exceeded expectations, reaching $138.1 million, which is 6% above the anticipated full-year estimate of $130 million. This strong performance was driven by a robust end to the year, with Q4 2023 revenues reaching $39.3 million[2].
Revenue Projections
For 2024, Catalyst Pharmaceuticals forecasts FYCOMPA's net revenues to be between $130 million and $135 million. This projection is based on the continued strong demand for the drug and the company's effective integration of the FYCOMPA business unit[2].
Financial Impact on Catalyst Pharmaceuticals
The acquisition of FYCOMPA has significantly bolstered Catalyst Pharmaceuticals' financial performance. The company's full-year total revenue for 2023 was $398.2 million, a substantial increase from the previous year. The integration of FYCOMPA is expected to be accretive to EBITDA and EPS in 2023 and beyond[2].
Market Synergies
The addition of FYCOMPA to Catalyst's portfolio has created significant synergies. The physician call points for FYCOMPA overlap about 45% with those for FIRDAPSE, another key product of Catalyst, allowing for more efficient commercial operations. This overlap is expected to enhance the company's overall revenue and cash flow generation[1].
Competitive Landscape
FYCOMPA is the first and only AMPA receptor antagonist marketed for epilepsy, giving it a unique position in the market. Eisai's decision to sell the U.S. rights to Catalyst was partly driven by its focus on other high-potential assets, such as the Alzheimer’s disease drug lecanemab[4].
Clinical Effectiveness and Safety
Real-world studies have demonstrated the effectiveness and safety of FYCOMPA. A large study presented at the American Epilepsy Society annual meeting evaluated over 5,000 patients and showed promising retention rates and seizure frequency reductions. However, the drug is associated with adverse effects such as hostility, aggression, and psychiatric events, which are dose-related and generally appear within the first six weeks of treatment[3].
Pricing Considerations
The pricing of FYCOMPA is influenced by several factors, including its unique mechanism of action, clinical efficacy, and the competitive landscape in the epilepsy treatment market. Given its status as a Schedule III controlled substance, pricing strategies must also consider regulatory and compliance aspects.
Future Outlook
Catalyst Pharmaceuticals is optimistic about the future of FYCOMPA, expecting continued growth driven by its strong commercial execution and the drug's market position. The company's forecast for 2024 reflects a confident outlook, with total net revenues projected to increase by 14% to 19% compared to 2023[2].
Key Takeaways
- Strong Revenue Performance: FYCOMPA's net revenues have exceeded expectations, contributing significantly to Catalyst Pharmaceuticals' total revenue.
- Market Synergies: The overlap in physician call points between FYCOMPA and FIRDAPSE enhances commercial efficiency.
- Unique Market Position: FYCOMPA is the first and only AMPA receptor antagonist for epilepsy, providing a competitive edge.
- Clinical Effectiveness: Real-world studies have shown promising results in terms of seizure frequency reduction and patient retention.
- Future Projections: Forecasted revenues for FYCOMPA are between $130 million and $135 million for 2024, with expected continued growth.
FAQs
Q: What is FYCOMPA used for? A: FYCOMPA is used in the treatment of epilepsy, specifically for partial-onset seizures and primary generalized tonic-clonic seizures in patients aged 4 and older[1].
Q: Who acquired the U.S. rights to FYCOMPA? A: Catalyst Pharmaceuticals acquired the U.S. rights to FYCOMPA from Eisai in January 2023[4].
Q: What are the forecasted revenues for FYCOMPA in 2024? A: Catalyst Pharmaceuticals forecasts FYCOMPA's net revenues to be between $130 million and $135 million for 2024[2].
Q: What are the common adverse effects associated with FYCOMPA? A: Common adverse effects include hostility, aggression, and psychiatric events, which are generally dose-related and appear within the first six weeks of treatment[1].
Q: How does FYCOMPA integrate with Catalyst's existing portfolio? A: The physician call points for FYCOMPA overlap about 45% with those for FIRDAPSE, enhancing commercial efficiency and synergies[1].
Sources
- Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII. Catalyst Pharmaceuticals.
- Earnings call: Catalyst Pharmaceuticals reports strong 2023 growth. Investing.com.
- Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA (Perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting. PR Newswire.
- Eisai peddles US rights to epilepsy drug Fycompa to Catalyst. FiercePharma.
More… ↓
